BRPI0906498A2 - Anticorpo ron e seus usos - Google Patents

Anticorpo ron e seus usos

Info

Publication number
BRPI0906498A2
BRPI0906498A2 BRPI0906498-2A BRPI0906498A BRPI0906498A2 BR PI0906498 A2 BRPI0906498 A2 BR PI0906498A2 BR PI0906498 A BRPI0906498 A BR PI0906498A BR PI0906498 A2 BRPI0906498 A2 BR PI0906498A2
Authority
BR
Brazil
Prior art keywords
ron antibody
ron
antibody
Prior art date
Application number
BRPI0906498-2A
Other languages
English (en)
Inventor
Hearther Huet
Veronique Bailly
Ellen Garber
Christilyn Graff
Steven Miklasz
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BRPI0906498A2 publication Critical patent/BRPI0906498A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0906498-2A 2008-01-22 2009-01-22 Anticorpo ron e seus usos BRPI0906498A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2277908P 2008-01-22 2008-01-22
PCT/US2009/000376 WO2009094148A2 (en) 2008-01-22 2009-01-22 Ron antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0906498A2 true BRPI0906498A2 (pt) 2015-07-14

Family

ID=40901578

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906498-2A BRPI0906498A2 (pt) 2008-01-22 2009-01-22 Anticorpo ron e seus usos

Country Status (11)

Country Link
US (1) US20090226442A1 (pt)
EP (1) EP2245066A2 (pt)
JP (1) JP2011509687A (pt)
KR (1) KR20100106590A (pt)
CN (1) CN101977937A (pt)
AU (1) AU2009206724A1 (pt)
BR (1) BRPI0906498A2 (pt)
CA (1) CA2712697A1 (pt)
IL (1) IL207129A0 (pt)
MX (1) MX2010008025A (pt)
WO (1) WO2009094148A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
US20130089554A1 (en) * 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
CA2787070A1 (en) * 2010-01-28 2011-08-04 Ian Kirby Cd127 binding proteins
WO2012000994A1 (en) * 2010-06-29 2012-01-05 C.N.R.S. Llt-1 antibodies with new functional properties
JP2013533746A (ja) 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｒｏｎ抗体
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CN105017420B (zh) * 2012-02-17 2019-05-28 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
KR102131371B1 (ko) * 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
WO2018052789A1 (en) 2016-09-08 2018-03-22 Pcm Targetech, Llc Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) * 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
WO2021030358A1 (en) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
CN114874323A (zh) * 2021-02-05 2022-08-09 上海医药集团股份有限公司 抗gitr抗体及其用途
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US20020002276A1 (en) * 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
WO2000018895A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
AU2002258798A1 (en) * 2001-04-13 2002-10-28 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
WO2002087618A1 (en) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US6867005B2 (en) * 2001-10-24 2005-03-15 Beckman Coulter, Inc. Method and apparatus for increasing the dynamic range and accuracy of binding assays
US20030157082A1 (en) * 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
DK1675961T3 (da) * 2003-10-24 2009-02-23 Oncalis Ag Fremgangsmåde til identifikation og/eller validering af receptortyrosinkinaseinhibitorer
US20090246205A1 (en) * 2004-05-13 2009-10-01 Imclone Systems, Inc Inhibition of macrophage-stimulating protein receptor (ron)
EP1745073A2 (en) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
WO2006094073A2 (en) * 2005-03-02 2006-09-08 Acadia Pharmaceuticals Inc. Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands
EA015992B1 (ru) * 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
US7452985B2 (en) * 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
UY31478A1 (es) * 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo

Also Published As

Publication number Publication date
JP2011509687A (ja) 2011-03-31
MX2010008025A (es) 2010-08-04
KR20100106590A (ko) 2010-10-01
IL207129A0 (en) 2010-12-30
CA2712697A1 (en) 2009-07-30
WO2009094148A3 (en) 2010-01-14
AU2009206724A1 (en) 2009-07-30
WO2009094148A2 (en) 2009-07-30
US20090226442A1 (en) 2009-09-10
EP2245066A2 (en) 2010-11-03
CN101977937A (zh) 2011-02-16

Similar Documents

Publication Publication Date Title
BRPI1012321A2 (pt) anticorpos anti-vegf e seus usos
BRPI0910746A2 (pt) reticuladores e seus usos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0921862A2 (pt) inibidores de raf e seus usos
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI0913640A2 (pt) substâncias policrômicas e seus usos
BRPI0908853A2 (pt) composto oligopeptídicos e seus usos
HUE056626T2 (hu) Antitestkészítmény
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
EP2371333A4 (en) THIN CLEANER ARTICLE
EP2358392A4 (en) ANTIBODY FORMULATION
EP2496707A4 (en) DEVELOPED ANTIBODY AGAINST TSLP
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
EP2482848A4 (en) Endoglin antibodies
FR2936364B1 (fr) Element magnetocalorique
PT3037529T (pt) Polipéptidos ph20 estendidos solúveis e suas utilizações
BRPI1006519A2 (pt) formulação de anticorpos
BRPI1010540A2 (pt) "anticorpos especéficos para dkk-1 e seus usos"
EP2318438A4 (en) ANTI-P2X7 PEPTIDES AND EPITOPES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.